A Revolution in Prostate Cancer Therapy
Avenda Health is a software and medical device company that works at the unique intersection of urology, oncology, and AI. It has developed a male lumpectomy product that treats prostate cancer while preserving the quality of life for men. Its approach aims to mitigate the 50% risk of significant complications from surgery or radiation entirely by mapping out the cancerous tumor using Artificial Intelligence (AI) and performing focal laser ablation (FLA) at the site. A urologist can perform the ablation in a clinic setting solely using local anesthesia. Avenda Health’s promise of an in-office treatment with minimal side effects is an attractive option for the hundreds of thousands of patients living with prostate cancer as well as their urologists.
Quick Facts for Investors
Why We Invested
Avenda Health is the only product performed in the physician office setting, using local anesthesia. It is also the only product that integrates treatment planning with therapy, resulting in maximum precision and the best quality of life outcomes. Relative to its competitors, Avenda Health is convenient, less invasive, more precise, has fewer side effects, and is highly scalable.
Avenda Health is entering the market at a time poised for a virtual cycle of growth. As prostate MRI rapidly grows (10x in the last four years), more patients are funneled to targeted biopsy to confirm the clinically significant disease. The 90% of urologists trained to perform those biopsies represent the customer base for Avenda Health’s FLA therapy, as the procedures require nearly the same technique. As Avenda Health’s FLA therapy is used more frequently and patient outcomes improve, the value of the biopsy increases, furthering the incentive to perform biopsies.
In addition to prostate cancer treatment, Avenda Health offers other promising applications. Eventually, the company aims to apply its imaging software across the entire care pathway of prostate cancer, including diagnosis, risk stratification, staging, and treatment monitoring. Today, the software platform can be used as a diagnostic aid in segmenting and targeting the biopsy, but its cancer mapping algorithm requires biopsy-confirmed prostate cancer. Eventually, Avenda Health hopes to use detailed MRI data alongside clinical data and labs to enable the software to identify clinically significant diseases without requiring a biopsy automatically.